Breakthrough in Cancer Treatment: Non-Toxic Bacterial Therapy
A team of scientists from the University of Massachusetts Amherst and Ernest Pharmaceuticals has made significant strides in developing a non-toxic bacterial therapy for cancer, known as BacID. This innovative approach promises a safer and more effective treatment for cancers with high mortality rates, such as liver, ovarian, and metastatic breast cancer. Clinical trials involving cancer patients are anticipated to commence in 2027.
The Science Behind BacID
The therapy utilizes genetically engineered strains of Salmonella to target tumors and control the release of cancer-fighting drugs within cancer cells. This method not only spares healthy tissue from damage but also allows for the delivery of significantly higher doses of therapy compared to the administered amount, thanks to the bacteria's ability to grow exponentially in tumors.
Controlled Activation and Safety Measures
A key feature of this third-generation delivery strain is the controlled activation of the bacteria's flagella, which enables it to invade cancer cells. This activation is triggered by an over-the-counter dose of aspirin, ensuring that the bacteria remain dormant in the tumor until the precise moment of activation. Additionally, the bacteria are engineered with a suicide circuit, causing them to rupture and deliver the therapy directly inside the cancer cells.
Pre-Clinical Success and Future Steps
In pre-clinical research with mouse models, the bacteria were injected intravenously, with the immune system rapidly clearing them from healthy tissues within two days. The bacteria continued to grow exponentially only within tumors, and on the third day, an oral dose of aspirin triggered the invasion of cancer cells and the delivery of therapy. The team is now focused on obtaining regulatory approval to begin clinical trials, marking a significant step forward in microbial-based cancer treatment.
Expert Insights
"This is exciting because we now have all the critical pieces for getting an effective bacterial treatment for cancer," says Neil Forbes, senior author of the research and professor of chemical engineering at UMass Amherst. Vishnu Raman, lead author and chief scientific officer of Ernest Pharmaceuticals, adds, "We wanted to make it as simple as possible. So the patient could get the infusion and three days later, at home, they just take an oral dose of aspirin."
This development represents a promising advancement in the fight against cancer, offering hope for more effective and less toxic treatment options in the near future.
